Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen

Oncogene

Volumn 26, Issue 57, 2007, Pages 7872-7884

  Hao, H ^a   D'Alincourt Salazar, M ^a   Kelley, K M M ^a   Shatnawi, A ^a   Mukherjee, S ^a   Shah, Y M ^a   Ratnam, M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Estrogen; Estrogen receptor; Folate receptor; Gene repression; SERM; TAFII30

Indexed keywords

DNA; ESTROGEN; ESTROGEN RECEPTOR; FOLATE RECEPTOR; TAMOXIFEN; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR SP1;

ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA FLANKING REGION; DNA RESPONSIVE ELEMENT; DOWN REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION;

CARRIER PROTEINS; CYCLOHEXIMIDE; DNA-BINDING PROTEINS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TAMOXIFEN; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID;

EID: 37149048758     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210592     Document Type: Article

References (42)

1. Aranda A, Pascual A. (2001). Nuclear hormone receptors and gene expression. Physiol Rev 81: 1269-1304.
2. Baniahmad A, Ha I, Reinberg D, Tsai S, Tsai MJ, O'Malley BW. (1993). Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA 90: 8832-8836.
3. Blobel GA, Sieff CA, Orkin SH. (1995). Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol 15: 3147-3153.
4. Butler JE, Kadonaga JT. (2002). The RNA polymerase II core promoter: a key component in the regulation of gene expression. Genes Dev 16: 2583-2592.
5. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. (2006). Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21: 555-564.
6. Dauvois S, White R, Parker MG. (1993). The antiestrogen ICI 182780disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106(Part 4): 1377-1388.
7. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. (2005). Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 19: 362-378.
8. Fondell JD, Brunel F, Hisatake K, Roeder RG. (1996). Unliganded thyroid hormone receptor alpha can target TATA-binding protein for transcriptional repression. Mol Cell Biol 16: 281-287.
9. Fondell JD, Roy AL, Roeder RG. (1993). Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: implications for active repression. Genes Dev 7: 1400-1410.
10. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574.
11. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. (2004). Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64: 1522-1533.
12. Glass CK, Rosenfeld MG. (2000). The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141.
13. Hall JM, Couse JF, Korach KS. (2001). The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869-36872.
14. Hao H, Qi H, Ratnam M. (2003). Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood 101: 4551-4560.
15. Hayashi S. (2004). Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacother 58: 1-9.
16. Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L. (1994). Human TAFII30is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 79: 107-117.
17. Kelley KM, Rowan BG, Ratnam M. (2003). Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 63: 2820-2828.
18. Kershah SM, Desouki MM, Koterba KL, Rowan BG. (2004). Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol Oncol 92: 304-313.
19. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono Ketal K et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
20. Masuyama H, Jefcoat Jr SC, MacDonald PN. (1997). The N-terminal domain of transcription factor IIB is required for direct interaction with the vitamin D receptor and participates in vitamin D-mediated transcription. Mol Endocrinol 11: 218-228.
21. McDonnell DP. (2005). The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res 11: 871s-877s.
22. Mengus G, May M, Carre L, Chambon P, Davidson I. (1997). Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Genes Dev 11: 1381-1395.
23. Moehren U, Eckey M, Baniahmad A. (2004). Gene repression by nuclear hormone receptors. Essays Biochem 40: 89-104.
24. Muscat GE, Burke LJ, Downes M. (1998). The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res 26: 2899-2907.
25. Parker MG. (1993). Action of 'pure' antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26: 131-137.
26. Pink JJ, Jordan VC. (1996). Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330.
27. Sadovsky Y, Webb P, Lopez G, Baxter JD, Fitzpatrick PM, Gizang-Ginsberg E et al. (1995). Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol Cell Biol 15: 1554-1563.
28. Safe S, Kim K. (2004). Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol 77: 1-36.
29. Saikawa Y, Price K, Hance KW, Chen TY, Elwood PC. (1995). Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. Biochemistry 34: 9951-9961.
30. Schmitt M, Bausero P, Simoni P, Queuche D, Geoffroy V, Marschal C et al. (1995). Positive and negative effects of nuclear receptors on transcription activation by AP-1 of the human choline acetyltransferase proximal promoter. J Neurosci Res 40: 152-164.
31. Schulman IG, Chakravarti D, Juguilon H, Romo A, Evans RM. (1995). Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation. Proc Natl Acad Sci USA 92: 8288-8292.
32. Smale ST. (2001). Core promoters: active contributors to combinatorial gene regulation. Genes Dev 15: 2503-2508.
33. Smale ST, Kadonaga JT. (2003). The RNA polymerase II core promoter. Annu Rev Biochem 72: 449-479.
34. Smith CL, O'Malley BW. (2004). Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71.
35. Stein B, Yang MX. (1995). Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15: 4971-4979.
36. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C et al. (2000). Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem 275: 22769-22779.
37. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS. (2006). Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem 281: 16272-16278.
38. Tong GX, Tanen MR, Bagchi MK. (1995). Ligand modulates the interaction of thyroid hormone receptor beta with the basal transcription machinery. J Biol Chem 270: 10601-10611.
39. Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM et al. (2005). ICI182780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 280: 3185-3196.
40. Wang DY, Fulthorpe R, Liss SN, Edwards EA. (2004). Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 18: 402-411.
41. Wong CW, Privalsky ML. (1998). Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol 18: 5500-5510.
42. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J et al. (2003). Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 22: 1336-1346.